Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by MrMugsyon Dec 15, 2022 8:20pm
162 Views
Post# 35174788

RE:Depreciation/Amortization

RE:Depreciation/AmortizationI would expect those numbers to be high - especially with this size of the Grupo buy.
The numbers will likely be high for 10 of 15 year - but that's just me guessing.

I think that's why it's important to look at EBITDA on a yoy basis to see if we're moving in the right direction.

With Paladin, we grew very slowly with very small purchases in the first 11-12 years.  We got a lot of debt in some smaller purchases and used that debt against our profits.

Even when we moved into Sub-Saharan Africa, it was initially in a small partnership - converted to a larger partnership down the road (never owning more than 44%) and then eventually sold to Endo.  Never really made a 100% buy as big as this one.  Therefore, effects were less obvious until revenues/earning were growing at a nice clip.

That's sort of how I remember it - was a long time ago.


<< Previous
Bullboard Posts
Next >>